Literature DB >> 19878978

Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience.

Matías Jurado1, Juan Luis Alcázar, Rafael Martinez-Monge.   

Abstract

OBJECTIVE: (1) To determine the accuracy of a standard clinical and radiological assessment of resectability in patients with previously irradiated recurrent cervical cancer (PIRCC), and (2) to report the outcome and prognostic factors in this high-risk population treated with an exenterative procedure.
METHODS: Forty-eight patients with centrally located (n=20, 41.7%) or lateralized (n=28, 58.3%) PIRCC treated with exenterative procedures were analyzed. All patients underwent standard assessment of resectability with pelvic exam and radiological studies. Patients with centrally located tumors were considered as resectable and lateralized tumors were deemed unresectable.
RESULTS: Complete surgical resection with negative margins (R0) was achieved in 28.6% of the patients with lateral recurrences and in 65.0% of the patients with central recurrences (p<0.019). After a median follow-up of 114.6 months (3.0-244.9 months), the 10-year local control rate for the whole group was 36.3%, 43.1% in the central PIRCC group and 31.5% in the lateral PIRCC group, respectively (p=0.290). Multivariate analysis showed that improved local control was significantly associated with the presence of negative margins (p=0.004). The 10-year distant failure rate was 69%, 56.6% in the central PIRCC group and 83.2% in the lateral PIRCC group (p=0.178), respectively. Multivariate analysis showed that the development of distant metastases was significantly correlated with the absence of local control (p=0.01). The 10-year disease-specific survival (DSS) for central and lateral PIRCC was 27.2% and 14.9%, respectively (p=0.239). Multivariate analysis showed that negative margins (p=0.001), local control (p=0.001) and distant control (p=0.006) were all significantly associated with improved DSS. Location of PIRCC (central vs. lateral) was irrelevant for DSS in completely resected (R0) patients. Overall morbidity rate was 65.0% and 73.3% for central and lateral PIRCC patients, respectively (p=0.528).
CONCLUSION: About one-third of the patients with lateral PIRCC classified as unresectable with non-surgical means may ultimately undergo complete (R0) resections and about one-third of the patients with centrally located PIRCC and judged as resectable will undergo non-curative (R1) resections. A curative (R0) resection significantly impacts local control rates, distant metastases-free rates and DSS.

Entities:  

Mesh:

Year:  2009        PMID: 19878978     DOI: 10.1016/j.ygyno.2009.09.035

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

Review 1.  Long-term experience with (laterally) extended endopelvic resection (LEER) in relapsed pelvic malignancies.

Authors:  Michael Höckel
Journal:  Curr Oncol Rep       Date:  2015-03       Impact factor: 5.075

2.  [Total pelvic exenteration].

Authors:  U Heger; M Koch; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2010-10       Impact factor: 0.955

3.  Clinical outcome of pelvic exenteration in patients with advanced or recurrent uterine cervical cancer.

Authors:  Sota Tanaka; Satoru Nagase; Michiko Kaiho-Sakuma; Tomoyuki Nagai; Hiroki Kurosawa; Masafumi Toyoshima; Hideki Tokunaga; Takeo Otsuki; Hiroki Utsunomiya; Tadao Takano; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2013-02-13       Impact factor: 3.402

4.  Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases.

Authors:  Nicolae Bacalbasa; Adina Croitoru; Irina Balescu; Mihaela Vilcu; Adrian Neacsu; Simona Dima; Iulian Brezean
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

5.  Pelvic exenteration: experience from a rural cancer center in developing world.

Authors:  Sampada B Dessai; Satheesan Balasubramanian; Vijay M Patil; Santam Chakraborty; Atanu Bhattacharjee; Syam Vikram
Journal:  Int J Surg Oncol       Date:  2015-02-08

6.  Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).

Authors:  Nathalie Arians; Robert Foerster; Joachim Rom; Matthias Uhl; Falk Roeder; Jürgen Debus; Katja Lindel
Journal:  Radiat Oncol       Date:  2016-03-18       Impact factor: 3.481

Review 7.  Image-Guided Brachytherapy for Salvage Reirradiation: A Systematic Review.

Authors:  Sophie Bockel; Sophie Espenel; Roger Sun; Isabelle Dumas; Sébastien Gouy; Philippe Morice; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2021-03-11       Impact factor: 6.639

8.  Value of tube combined with real-time ultrasound-guided accurate interstitial high-dose-rate brachytherapy for post-operative pelvic side-wall recurrences of cervical cancer.

Authors:  Keita Mamady; Xi Chen; Bah Malick; Zhaohui Fang; Huixian Niu; Traoré Bangaly; Hong Liu
Journal:  J Contemp Brachytherapy       Date:  2021-12-30

9.  Surgical results of pelvic exenteration in the treatment of gynecologic cancer.

Authors:  Andrea Petruzziello; William Kondo; Sergio B Hatschback; João A Guerreiro; Flávio Panegalli Filho; Cristiano Vendrame; Murilo Luz; Reitan Ribeiro
Journal:  World J Surg Oncol       Date:  2014-09-08       Impact factor: 2.754

10.  Opportunities and Limitations of Pelvic Exenteration Surgery.

Authors:  Björn Lampe; Verónica Luengas-Würzinger; Jürgen Weitz; Stephan Roth; Friederike Rawert; Esther Schuler; Sabrina Classen-von Spee; Nando Fix; Saher Baransi; Anca Dizdar; Peter Mallmann; Klaus-Dieter Schaser; Andreas Bogner
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.